Overview: Anti-Mitochondrial M2 Antibody TestIntroduction: The Anti-Mitochondrial M2 Antibody Test detects antibodies linked to primary biliary cholangitis, a liver disease causing fatigue, itching, or jaundice. Aligned with 2023 AASLD guidelines, it uses an immunoassay for high specificity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected liver autoimmune conditions.
Other Names: Anti-M2 Assay, Primary Biliary Cholangitis Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Mitochondrial antibody testing began in the 1960s. Anti-M2 assays emerged in the 1980s, and by the 2000s, immunoassays improved specificity for primary biliary cholangitis.
Purpose: Diagnoses primary biliary cholangitis, guides treatment, and monitors disease activity in patients with fatigue, itching, or jaundice.
Test Parameters: 1. Anti Mitochondrial Antibody M2
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like fatigue or jaundice, and list medications like ursodeoxycholic acid.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document liver symptoms, autoimmune disease history, or family history of liver diseases. Include current medications, especially those affecting liver function.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for treatment or liver imaging.
Procedural Considerations: Uses an immunoassay to measure anti-mitochondrial M2 antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm primary biliary cholangitis, prompting ursodeoxycholic acid therapy. Negative results may require liver function tests for confirmation.
Specialist Consultation: Consult a hepatologist for result interpretation. A gastroenterologist referral is advised for advanced cases.
Additional Supporting Tests: Liver function tests, AMA immunofluorescence, or liver biopsy to confirm primary biliary cholangitis or assess liver damage.
Test Limitations: False negatives may occur with early disease. Results require clinical correlation with liver function tests.
References: AASLD PBC Guidelines, 2023; Hepatology, Lindor KD, 2022.
